Practolol was administered in 47 instances of acute arrhythmia, mainly of supraventricular origin. The drug was highly effective in 75 per cent of cases, including those with acute myocardial infarction. The therapeutic dose ranged from 5 to I8o mg. Despite administration of doses up to 500 mg, no serious side effects were noted.
The beta-adrenergic blocking agents are gaining increasingly wide application in the treatment of cardiac arrhythmias (Gibson and Sowton, I969) . Propranolol is the best known and, heretofore, the most commonly employed drug belonging to this group. However, the usefulness of propranolol in the management of acute disturbances of the cardiac rhythm is limited owing to its direct depressant action on the myocardium, to the blockade of the beta-adrenergic receptors of the bronchial musculature, and to the action on the peripheral circulation.
The purpose of the present study was the evaluation of the usefulness of one of the newer beta-adrenergic blocking agents, practolol,' in the management of acute arrhythmias.
Practolol exerts selective action on myocardial beta-receptors (Bussmann, Rauh, and Krayenbuehl, 1970; Dunlop and Shanks, 1968 Table i ). The underlying conditions were atherosclerotic' heart disease (20 patients), acute myocardial infarction (Iii patients), valvular heart disease (5 patients), and hyperthyroidism, scleroderma, and cor pulmonale (i patient each). In 36 instances, practolol was the first antiarrhythmic drug tried, and in ii instances other drugs or electrical cardioversion had been previously employed with no benefit. In 2I patients arrhythmia was associated with left ventricular failure. The drug was administered intravenously, the dose ranging from 5 to 500 mg, on average 66 mg, and the initial injection speed did not exceed 5 mg a minute. The speed of injection depended upon the individual response of the patient and on the dose of the drug, and ranged from 2 to 6o minutes.
Results
The results are summarized in Table i. In the instances of successful termination of arrhyth- (Jewitt et al., I969; Vohra et al., I970) .
Conclusions
Practolol, a beta-adrenergic receptor blocking agent, is obviously effective in the management of paroxysmal arrhythmias. The present study is concerned mainly with supraventricular arrhythmias.
Practolol also slows the ventricular rate in cases of chronic atrial fibrillation with rapid ventricular rates and in sinus tachycardia. This effect makes the drug particularly useful for patients in whom ventricular hyperexcitability precludes digitalization.
For full achievement of the antiarrhythmic effect ofpractolol, the doses ofthe drug should be individually established in the range from a few to several hundred milligrams.
Untoward side effects, such as a transient fall in systolic blood pressure and disturbances of myocardial conduction, are rare and disappear when the drug is discontinued.
The above properties of practolol make this compound an efficacious and safe drug for the management of arrhythmias associated with acute myocardial infarction.
Samples of practolol (Eraldin) were kindly supplied by ICI, Ltd, England. acute arrhythmias. 
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